How to Help Your Patients Save Money on Miebo: A Provider's Guide to Savings Programs

Author

Peter Daggett

Summarize with AI

Overview: Miebo's Savings Landscape in 2026
1. MIEBO MySavings Program (Copay Card)
2. BlinkRx: The Preferred Pharmacy Channel
3. GoodRx and SingleCare (For Uninsured and Cash-Pay Patients)
4. Insurance Coverage Optimization Strategies
Quick Reference by Patient Type
The Bottom Line for Providers

A comprehensive provider guide to all available Miebo savings programs in 2026: copay cards, BlinkRx, discount programs, Medicare strategies, and formulary appeals.

Miebo (perfluorohexyloctane) carries a retail price of $800 to $1,200 per 3 mL bottle — a 30-day supply. For many of your patients, particularly those on Medicare, Medicaid, or without insurance, this price is a significant barrier to starting or maintaining therapy. Understanding the full landscape of available savings programs empowers your practice to help patients stay on therapy while managing costs effectively.

Overview: Miebo's Savings Landscape in 2026

There are four main categories of assistance available for Miebo patients:

Manufacturer copay assistance (for commercially insured patients)
BlinkRx digital pharmacy (savings + delivery for all eligible patients)
Third-party discount programs (GoodRx, SingleCare — for uninsured/cash-pay patients)
Insurance coverage optimization (PA, exceptions, and Medicare Part D tools)

1. MIEBO MySavings Program (Copay Card)

The MIEBO MySavings Program is Bausch + Lomb's manufacturer copay assistance program. Eligible commercially insured patients may pay

as little as $0 per fill for new prescriptions and refills.

Key program details for providers:

Eligible patients: Must have active commercial insurance coverage for the prescription. Self-pay (cash-pay) patients without insurance are not eligible.
NOT eligible: Medicare (all parts including Medicare Advantage), Medicaid, TRICARE, VA, CHAMPUS, Puerto Rico Government Health Insurance Plan, and any other federal/state government health program
How to activate: Patients activate the card at MIEBO.CopaySavingsProgram.com or via the BlinkRx automated process. The card can be digital or printed.
How it works at the pharmacy: After the insurance claim is processed, the copay card pays the remainder up to the program maximum. At BlinkRx, this is applied automatically without the patient needing to present a card.
At Walgreens: Eligible commercially insured patients who obtain PA may pay as little as $69. Without PA, eligible patients may pay as little as $215.

2. BlinkRx: The Preferred Pharmacy Channel

BlinkRx is Bausch + Lomb's preferred pharmacy partner and the most seamless pathway to savings + access for your Miebo patients. Here's what it does for your patients and your practice:

Automatically identifies and applies all applicable savings (copay card, insurance, etc.)
Handles prior authorization — contacts your office only if additional clinical documentation is needed
Texts patients with their copay amount within ~15 minutes of prescription receipt
Delivers Miebo with free shipping nationally
Provides pharmacist support for refill adherence and patient questions

For your practice, defaulting all Miebo e-prescriptions to BlinkRx U.S. (Boise, ID) is the highest-yield single change you can make to improve patient access and reduce PA-related callbacks.

3. GoodRx and SingleCare (For Uninsured and Cash-Pay Patients)

For patients without insurance — or those whose insurance doesn't cover Miebo and who don't qualify for the copay card — third-party discount programs provide meaningful savings:

GoodRx: Prices Miebo at approximately $778 per 3 mL bottle (compared to retail of $800–$1,200). More than 15% savings. The GoodRx coupon can be printed or shown digitally at the pharmacy.
SingleCare: Prices Miebo at approximately $810 at participating pharmacies.

Note: Discount cards cannot be combined with insurance. Advise patients to compare their insurance copay to the GoodRx price and use whichever is lower.

4. Insurance Coverage Optimization Strategies

As of January 2025, Miebo has broad formulary coverage: approximately 75% commercial, 65% Medicare Part D, and nearly all Medicaid plans. For the 25% of commercial plans that don't cover it, or for plans that require step therapy or PA, these strategies can improve coverage outcomes:

Prior Authorization with strong documentation: Document MGD diagnosis with meibography if available, corneal staining results, TBUT, and prior therapy failures. Specificity matters — "inadequate response to artificial tears" is stronger when accompanied by documented exam findings.
Formulary exception requests: For non-formulary patients, request a formulary exception by documenting medical necessity. The argument that Miebo's anti-evaporative mechanism is unique among FDA-approved DED therapies is compelling.
Medicare Part D benefits in 2025+: The 2025 Part D redesign caps out-of-pocket drug costs at $2,000/year. The Medicare Prescription Payment Plan allows patients to spread drug costs across the year rather than paying large amounts upfront. These changes significantly reduce the burden for Medicare patients on Miebo.

Quick Reference by Patient Type

Commercially insured: BlinkRx + copay card → target $0 copay
Medicare Part D: Submit PA if required; advise patients on the $2,000 cap and Payment Plan; BlinkRx for product trial if applicable
Medicaid: Coverage is broad; check state-specific PA requirements; Medicaid cost-sharing is typically low
Uninsured/cash-pay: GoodRx (~$778) or SingleCare (~$810); no manufacturer copay card available for this group

The Bottom Line for Providers

Cost should not be the reason your patients discontinue Miebo therapy. With proactive use of the MIEBO MySavings Program, BlinkRx, and insurance coverage tools, the majority of your patients can access Miebo at a manageable cost. Build these savings pathways into your front-office Miebo workflow. For real-time pharmacy availability support, medfinder for Providers can help your staff route prescriptions to pharmacies that have it in stock.

Frequently Asked Questions

No. The MIEBO MySavings copay card is explicitly not valid for Medicare beneficiaries, including Medicare Advantage, Medicare Part D, and all other Parts. For Medicare patients, coverage through their Part D plan is the primary option. The 2025 Part D $2,000 out-of-pocket cap provides meaningful protection for high-cost drugs like Miebo.

Almost all Medicaid plans cover Miebo, but some states require prior authorization. Check your state's specific Medicaid PA requirements. Medicaid copays for covered drugs are typically very low. The manufacturer's copay card is not valid for Medicaid patients, but this is usually not needed given Medicaid's low cost-sharing.

Add BlinkRx U.S. (Boise, Idaho) to your EMR's preferred pharmacy list. Most major EHR platforms (Epic, Athena, Modernizing Medicine) have BlinkRx available in the e-prescribing pharmacy directory. For paper-based practices, BlinkRx accepts faxed or phoned prescriptions.

The copay card can reduce out-of-pocket costs for commercially insured patients, but patients with HSA (Health Savings Account) plans should be aware of potential IRS restrictions on combining HSA funds with manufacturer copay assistance. Advise affected patients to consult their benefits administrator. For non-HSA plans, the copay card works as intended.

If the initial PA is denied, you can request a peer-to-peer review with the insurance company's medical director. A well-documented appeal — citing the unique anti-evaporative mechanism of Miebo, documented MGD, and failure of alternative therapies — often succeeds on appeal. If appeals fail, formulary exception requests and switching to an alternative (cyclosporine, lifitegrast) are the remaining options.

Medfinder Editorial Standards

Medfinder's mission is to ensure every patient gets access to the medications they need. We are committed to providing trustworthy, evidence-based information to help you make informed health decisions.

Read our editorial standards